A California drugmaker that tames the stress hormone cortisol, which the body pumps out in excess in some illnesses. Its best-known medicine, Korlym, treats Cushing's syndrome, a condition where too much cortisol causes high blood sugar and other troubles. Founded in 1998 by two Stanford psychiatrists, the company got its name from a mashup of "cortisol" and "concept." Its founding idea grew out of a Stanford researcher's hunch that the abortion pill mifepristone could also block cortisol's effects — a hunch that later became its flagship drug.
Guyer WilliamChief Development Officer · 14 transactions
+10.3%
29.5K†
82.8K
—
80.0K
Lyon Joseph DouglasSee Remarks · 7 transactions
-33.1%
7.0K
1.9K
—
5.0K
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -305.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.